NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society

by Eddie Staley, Benzinga Editor
June 18, 2012 4:10 PM | 13 seconds read | Make a Comment
Loading...
Loading...
NPS Pharmaceuticals, Inc.
NPSP
today reported that three abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism will be presented at ENDO 2012, the annual meeting of The Endocrine Society in Houston, TX, June 23-26, 2012.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsFDAEvents
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!